Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why a Watch or Bracelet Might Save Lives Soon

According to a recent study published by Markets and Markets, the wearable medical device market is predicted to reach $14.1 billion by 2022 from USD 5.31 billion in 2016. Players in this highly competitive industry design and manufacture diverse technology, from blood glucose meters to heart monitors to pain management devices, but they have one…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

According to a recent study published by Markets and Markets, the wearable medical device market is predicted to reach $14.1 billion by 2022 from USD 5.31 billion in 2016. Players in this highly competitive industry design and manufacture diverse technology, from blood glucose meters to heart monitors to pain management devices, but they have one thing in common: their field is exploding with innovation.

Changes in the industry did not happen overnight, however. Let’s take a look at how we got here and where we might be going.

The mobile health industry has been defined as “the generation, accumulation, and exchange of medical information through mobile and wireless tools.” As such, the industry’s history is intertwined with that of mobile tech in general, which includes basic tools from calculators to the later use of mobile phones.

It is difficult to pinpoint exactly when “wearable technology” began, considering that the 1600s saw the use of an abacus necklace, but the precursor to today’s devices is more closely associated with the advent of the calculator watch in the 1970s.

Today’s medical devices specifically are linked to the development of mobile computer technology. The crossover into medical use seems to have occurred with the advent of fitness monitoring, in the form of digital bracelets and other wearables that track heart rate and blood pressure, and from there the technology broadened to include glucose meters and other monitors aimed at the self-management of chronic conditions.

After their integration into wellness programs, these devices made their way into clinical settings, where they were used to provide more objective data. Over time, their use has evolved to include therapeutic devices for pain management, respiratory therapy, and insulin control; and diagnostics and monitoring services for vital signs, glucose, sleep habits, and even neurological activity.

The impact of medical wearable technology is potentially huge, for a variety of reasons: the devices are “user-friendly, unobtrusive, and ‘connected’ with features such as wireless data transmission, real-time feedback, and alerting mechanisms,” according to HIT Consultant.

In addition, their advantages extend beyond healthcare itself and empower patients to take ownership of their own health. Furthermore, they offer peace of mind to those who live alone as well as their loved ones, knowing there is an extra layer of security and “communication” available to the ailing family member. It also allows the individual with health concerns to maintain their autonomy.

While there are still issues to be worked out, including billing logistics and data use and related privacy concerns, the wearable medical device is volcanic in its growth and poised to disrupt the medical industry in the next several years. If some of these trouble spots can be smoothed out, there is “infinite opportunity for medical devices to transform healthcare” and “potential for them to become an instrumental part of our daily lives” by reducing healthcare costs, increasing peace of mind, and fostering ownership of our health and wellness.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512